JP2005521713A5 - - Google Patents

Download PDF

Info

Publication number
JP2005521713A5
JP2005521713A5 JP2003579812A JP2003579812A JP2005521713A5 JP 2005521713 A5 JP2005521713 A5 JP 2005521713A5 JP 2003579812 A JP2003579812 A JP 2003579812A JP 2003579812 A JP2003579812 A JP 2003579812A JP 2005521713 A5 JP2005521713 A5 JP 2005521713A5
Authority
JP
Japan
Prior art keywords
composition according
pharmaceutical composition
furyl
phenyl
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2003579812A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005521713A (ja
Filing date
Publication date
Priority claimed from US10/147,445 external-priority patent/US7166293B2/en
Application filed filed Critical
Publication of JP2005521713A publication Critical patent/JP2005521713A/ja
Publication of JP2005521713A5 publication Critical patent/JP2005521713A5/ja
Pending legal-status Critical Current

Links

JP2003579812A 2002-03-29 2003-03-31 血管新生阻害剤 Pending JP2005521713A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US36889202P 2002-03-29 2002-03-29
US10/147,445 US7166293B2 (en) 2002-03-29 2002-05-16 Angiogenesis inhibitors
PCT/US2003/009968 WO2003082274A1 (en) 2002-03-29 2003-03-31 Angiogenesis inhibitors

Publications (2)

Publication Number Publication Date
JP2005521713A JP2005521713A (ja) 2005-07-21
JP2005521713A5 true JP2005521713A5 (enExample) 2006-04-06

Family

ID=28456687

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003579812A Pending JP2005521713A (ja) 2002-03-29 2003-03-31 血管新生阻害剤

Country Status (10)

Country Link
US (2) US7166293B2 (enExample)
EP (1) EP1496894A4 (enExample)
JP (1) JP2005521713A (enExample)
KR (2) KR20100102746A (enExample)
CN (1) CN1642542B (enExample)
AU (1) AU2003222148C1 (enExample)
CA (1) CA2478918A1 (enExample)
NZ (1) NZ535990A (enExample)
TW (1) TWI296524B (enExample)
WO (1) WO2003082274A1 (enExample)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7166293B2 (en) 2002-03-29 2007-01-23 Carlsbad Technology, Inc. Angiogenesis inhibitors
US20050209252A1 (en) * 2002-03-29 2005-09-22 Che-Ming Teng Cancer treatment
US20050119278A1 (en) * 2002-05-16 2005-06-02 Che-Ming Teng Anti-angiogenesis methods
US20040198798A1 (en) * 2003-04-07 2004-10-07 Park Jong-Wan Method for inhibiting tumor angiogenesis and tumor growth
US20050096370A1 (en) * 2003-04-07 2005-05-05 Bizbiotech Co., Ltd. Method for inhibiting tumor angiogenesis and tumor growth
US7429596B2 (en) * 2003-06-20 2008-09-30 The Regents Of The University Of California 1H-pyrrolo [2,3-D] pyrimidine derivatives and methods of use thereof
CA2530679A1 (en) 2003-06-30 2005-04-07 Hif Bio, Inc. Compounds for treating angiogenesis
CN100516049C (zh) 2004-11-16 2009-07-22 永信药品工业股份有限公司 抗血管生成药n2-(取代的芳基甲基)-3-(取代的苯基)吲唑的合成
US9512125B2 (en) * 2004-11-19 2016-12-06 The Regents Of The University Of California Substituted pyrazolo[3.4-D] pyrimidines as anti-inflammatory agents
TW200732305A (en) * 2005-12-23 2007-09-01 Yung Shin Pharmaceutical Ind Cancer chemotherapy
KR101499783B1 (ko) * 2006-04-04 2015-03-09 더 리젠트스 오브 더 유니이버시티 오브 캘리포니아 키나제 길항물질
US20080252028A1 (en) * 2007-04-16 2008-10-16 Ming-Tai Huang Shock absorbing device for toy stroller
US20110160232A1 (en) * 2007-10-04 2011-06-30 Pingda Ren Certain chemical entities and therapeutic uses thereof
US8193182B2 (en) 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
AU2009204483B2 (en) 2008-01-04 2014-03-13 Intellikine, Llc Certain chemical entities, compositions and methods
JP5547099B2 (ja) * 2008-03-14 2014-07-09 インテリカイン， エルエルシー キナーゼ阻害剤および使用方法
US8993580B2 (en) 2008-03-14 2015-03-31 Intellikine Llc Benzothiazole kinase inhibitors and methods of use
US20110224223A1 (en) * 2008-07-08 2011-09-15 The Regents Of The University Of California, A California Corporation MTOR Modulators and Uses Thereof
MX2011000216A (es) * 2008-07-08 2011-03-29 Intellikine Inc Inhibidores de cinasa y metodos para su uso.
WO2010036380A1 (en) 2008-09-26 2010-04-01 Intellikine, Inc. Heterocyclic kinase inhibitors
WO2010045542A2 (en) 2008-10-16 2010-04-22 The Regents Of The University Of California Fused ring heteroaryl kinase inhibitors
US8476431B2 (en) * 2008-11-03 2013-07-02 Itellikine LLC Benzoxazole kinase inhibitors and methods of use
WO2010129816A2 (en) 2009-05-07 2010-11-11 Intellikine, Inc. Heterocyclic compounds and uses thereof
WO2011047384A2 (en) 2009-10-16 2011-04-21 The Regents Of The University Of California Methods of inhibiting ire1
JP5951600B2 (ja) 2010-05-21 2016-07-13 インフィニティー ファーマシューティカルズ， インコーポレイテッド キナーゼ調節のための、化合物、組成物および方法
US8901133B2 (en) 2010-11-10 2014-12-02 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
CN102485724B (zh) * 2010-12-06 2015-08-12 中国人民解放军军事医学科学院毒物药物研究所 取代噻吩基吡唑并吡啶类化合物及其医药用途
KR20180080358A (ko) 2011-01-10 2018-07-11 인피니티 파마슈티칼스, 인코포레이티드 이소퀴놀린온 및 이의 고체 형태의 제조 방법
JP6130305B2 (ja) 2011-02-23 2017-05-17 インテリカイン， エルエルシー キナーゼ阻害剤の組み合わせおよびそれらの使用
CN103930422A (zh) 2011-07-19 2014-07-16 无限药品股份有限公司 杂环化合物及其用途
EP2734530A1 (en) 2011-07-19 2014-05-28 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
CN103998442B (zh) 2011-08-29 2016-09-14 无限药品股份有限公司 杂环化合物及其用途
MX370814B (es) 2011-09-02 2020-01-08 Univ California Pirazolo[3,4-d]pirimidinas sustituidas y usos de las mismas.
UA111754C2 (uk) 2011-10-06 2016-06-10 Байєр Фарма Акцієнгезелльшафт Заміщені бензиліндазоли для застосування як інгібіторів bub1-кінази для лікування гіперпроліферативних захворювань
ES2638144T3 (es) 2011-12-21 2017-10-18 Bayer Intellectual Property Gmbh Bencilpirazoles sustituidos
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US8828998B2 (en) 2012-06-25 2014-09-09 Infinity Pharmaceuticals, Inc. Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
WO2014052669A1 (en) 2012-09-26 2014-04-03 The Regents Of The University Of California Modulation of ire1
IL291945B2 (en) 2012-11-01 2025-11-01 Infinity Pharmaceuticals Inc Treatment of cancers using pi3 kinase isoform modulators
US9481667B2 (en) 2013-03-15 2016-11-01 Infinity Pharmaceuticals, Inc. Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
WO2015051241A1 (en) 2013-10-04 2015-04-09 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
MX389256B (es) 2013-10-04 2025-03-20 Infinity Pharmaceuticals Inc Compuestos heterociclicos y usos de los mismos.
CA2940144C (en) * 2014-02-20 2023-06-13 Cornell University Substituted indazol-3-yl derivatives and pharmaceutical compositions thereof useful as inhibitor of fascin
EP4066834A1 (en) 2014-03-19 2022-10-05 Infinity Pharmaceuticals, Inc. Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders
US20150320755A1 (en) 2014-04-16 2015-11-12 Infinity Pharmaceuticals, Inc. Combination therapies
MX389591B (es) 2014-08-29 2025-03-20 Tes Pharma S R L INHIBIDORES DE ACIDO A-AMINO-ß-CARBOXIMUCONICO SEMIALDEHIDO DESCARBOXILASA
CR20170100A (es) 2014-09-19 2017-04-24 Bayer Pharma Aktiengesellchaft Indazoles sustituidos con bencilo como inhibidores bub1
WO2016054491A1 (en) 2014-10-03 2016-04-07 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
CN108349985A (zh) 2015-09-14 2018-07-31 无限药品股份有限公司 异喹啉酮的固体形式、其制备方法、包含其的组合物及其使用方法
US10759806B2 (en) 2016-03-17 2020-09-01 Infinity Pharmaceuticals, Inc. Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as PI3K kinase inhibitors
WO2017214269A1 (en) 2016-06-08 2017-12-14 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
CA3028718A1 (en) 2016-06-24 2017-12-28 Infinity Pharmaceuticals, Inc. Combination therapies
AR109595A1 (es) 2016-09-09 2018-12-26 Incyte Corp Compuestos de pirazolopirimidina y usos de estos como inhibidores de hpk1
WO2018049214A1 (en) 2016-09-09 2018-03-15 Incyte Corporation Pyrazolopyridine derivatives as hpk1 modulators and uses thereof for the treatment of cancer
TWI771319B (zh) 2016-09-09 2022-07-21 美商英塞特公司 吡唑并吡啶化合物及其用途
US10280164B2 (en) 2016-09-09 2019-05-07 Incyte Corporation Pyrazolopyridone compounds and uses thereof
WO2018152220A1 (en) 2017-02-15 2018-08-23 Incyte Corporation Pyrazolopyridine compounds and uses thereof
US10722495B2 (en) 2017-09-08 2020-07-28 Incyte Corporation Cyanoindazole compounds and uses thereof
US10745388B2 (en) 2018-02-20 2020-08-18 Incyte Corporation Indazole compounds and uses thereof
WO2019164847A1 (en) 2018-02-20 2019-08-29 Incyte Corporation Indazole compounds and uses thereof
US10800761B2 (en) 2018-02-20 2020-10-13 Incyte Corporation Carboxamide compounds and uses thereof
AR117398A1 (es) 2018-03-12 2021-08-04 Abbvie Inc Inhibidores de la señalización mediada por tirosina cinasa 2
US11299473B2 (en) 2018-04-13 2022-04-12 Incyte Corporation Benzimidazole and indole compounds and uses thereof
US10899755B2 (en) 2018-08-08 2021-01-26 Incyte Corporation Benzothiazole compounds and uses thereof
MA53726A (fr) 2018-09-25 2022-05-11 Incyte Corp Composés pyrazolo[4,3-d]pyrimidine en tant que modulateurs des alk2 et/ou fgfr
PE20221419A1 (es) 2019-08-06 2022-09-20 Incyte Corp Formas solidas de un inhibidor de hpk1
KR102823891B1 (ko) * 2020-01-14 2025-06-20 서울대학교산학협력단 혈관생성 저해 효과를 가지는 n-페닐벤조티아졸-2-아민 화합물 및 그를 포함하는 약제학적 조성물
CN117924280B (zh) * 2024-03-20 2024-07-12 中国人民解放军军事科学院军事医学研究院 取代噻吩基-5-氟-1h-吡唑并吡啶类化合物及其用途

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2928079B2 (ja) * 1994-02-14 1999-07-28 永信薬品工業股▲ふん▼有限公司 １−（置換ベンジル）−３−（置換アリール）縮合ピラゾール類、その製造法及びその用途
US6235741B1 (en) * 1997-05-30 2001-05-22 Merck & Co., Inc. Angiogenesis inhibitors
DE19744026A1 (de) * 1997-10-06 1999-04-08 Hoechst Marion Roussel De Gmbh Pyrazol-Derivate, ihre Herstellung und ihre Verwendung in Arzneimitteln
WO1999055335A1 (en) * 1998-04-30 1999-11-04 Basf Aktiengesellschaft Substituted tricyclic pyrazole derivatives with protein kinase activity
WO2000012110A2 (en) * 1998-08-26 2000-03-09 Queen's University At Kingston Use of anti(w)pressor agents for vascular remodeling in genital dysfunction
PE20010306A1 (es) 1999-07-02 2001-03-29 Agouron Pharma Compuestos de indazol y composiciones farmaceuticas que los contienen utiles para la inhibicion de proteina kinasa
US6867348B1 (en) * 1999-12-16 2005-03-15 Xenogen Corporation Methods and compositions for screening for angiogenesis modulating compounds
YU54202A (sh) 2000-01-18 2006-01-16 Agouron Pharmaceuticals Inc. Jedinjenja indazola, farmaceutske smeše i postupci za stimulisanje i inhibiranje ćelijske proliferacije
EP1251840A2 (en) 2000-01-26 2002-10-30 Cedars-Sinai Medical Center Method for using potassium channel activation for delivering a medicant to an abnormal brain region and/or a malignant tumor
US7018979B1 (en) * 2000-01-26 2006-03-28 Cedars-Sinai Medical Center Method for using potassium channel agonists for delivering a medicant to an abnormal brain region and/or a malignant tumor
GB0002666D0 (en) * 2000-02-04 2000-03-29 Univ London Blockade of voltage dependent sodium channels
US6387942B2 (en) * 2000-06-19 2002-05-14 Yung Shin Pharmaceutical Ind. Co. Ltd Method of treating disorders related to protease-activated receptors-induced cell activation
JP2002080367A (ja) * 2000-06-23 2002-03-19 Yung Shin Pharmaceutical Industry Co Ltd プロテアーゼ活性化受容体誘導性の細胞活性を阻害する薬剤
US20020041880A1 (en) * 2000-07-05 2002-04-11 Defeo-Jones Deborah Method of treating cancer
US6897231B2 (en) 2000-07-31 2005-05-24 Signal Pharmaceuticals, Inc. Indazole derivatives as JNK inhibitors and compositions and methods related thereto
AU2002212996A1 (en) * 2000-09-28 2002-04-08 Non-Invasive Monitoring Systems, Inc. External addition of pulses to fluid channels of body to release or suppress endothelial mediators and to determine effectiveness of such intervention
US20020159986A1 (en) * 2001-01-12 2002-10-31 John Langenfeld Bone morphogenetic protein-2 in the treatment and diagnosis of cancer
US6518294B2 (en) * 2001-01-24 2003-02-11 Yung Shin Pharmaceutical Ind. Co. Fused pyrazolyl compounds
KR100465666B1 (ko) 2001-09-27 2005-01-13 (주)비즈바이오텍 와이 씨-1을 유효 성분으로 함유하는 약학적 조성물
US7781413B2 (en) * 2001-10-31 2010-08-24 Board Of Regents, The University Of Texas System SEMA3B inhibits tumor growth and induces apoptosis in cancer cells
TWI264304B (en) * 2002-01-25 2006-10-21 Yung Shin Pharm Ind Co Ltd Methods of treating sepsis
TW200302722A (en) * 2002-02-13 2003-08-16 Astrazeneca Ab Therapeutic agents
US7166293B2 (en) 2002-03-29 2007-01-23 Carlsbad Technology, Inc. Angiogenesis inhibitors
US20050119278A1 (en) * 2002-05-16 2005-06-02 Che-Ming Teng Anti-angiogenesis methods
US20050096370A1 (en) * 2003-04-07 2005-05-05 Bizbiotech Co., Ltd. Method for inhibiting tumor angiogenesis and tumor growth
CA2530679A1 (en) 2003-06-30 2005-04-07 Hif Bio, Inc. Compounds for treating angiogenesis

Similar Documents

Publication Publication Date Title
JP2005521713A5 (enExample)
JP2005502635A5 (enExample)
JP2022121594A5 (enExample)
JP2009502743A5 (enExample)
JP2006526590A5 (enExample)
JP2008508304A5 (enExample)
JP2010540556A5 (enExample)
JP2007511504A5 (enExample)
JP2005511547A5 (enExample)
JP2010511721A5 (enExample)
JP2008510770A5 (enExample)
RU2005128190A (ru) Ингибиторы фактора подавления миграции макрофагов (фпм) и способы их идентификации
EP1818325A3 (en) 3,4-DI-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands
JP2006523216A5 (enExample)
CA2540163A1 (en) Thrombin receptor antagonists
JP2015508103A5 (enExample)
JP2006504738A5 (enExample)
JP2007519721A5 (enExample)
JP2008536833A5 (enExample)
JP2004528385A5 (enExample)
JP2002527414A5 (enExample)
JP2008513510A5 (enExample)
JP2009541387A5 (enExample)
JP2007502817A5 (enExample)
JP2006515866A5 (enExample)